# US 2004/0203108 A1 · IgA1 protease fragment as carrier peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0203108 A1
- Document ID: US20040203108A1
- Status: Published application
- Kind: A1
- Application number: 10/841,324
- Filed: 2004-05-07
- Published: 2004-10-14
- Earliest claimed: 1997-01-21
- Assignees: Max-Planck-Gesellschaft zur Forderung Der Wissenschaffen E.V. Berlin; Pasteur Merieux Serums et Vaccins
- Inventors: Mark Achtman; Monique Moreau
- Web page: https://patentgrep.com/patent/US20040203108A1

## CPC

- A61K 39/385: Haptens or antigens, bound to carriers
- C12N 9/52: derived from bacteria {or Archaea}
- A61K 2039/6037: {Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention is concerned with a fragment of IgA1-protease having 40 to 200 amino acid residues and comprising at least 40 amino acids of an amino acid sequence as shown in SEQ ID NO:1, beginning with the amino acid in any one of positions 1 to 5 and ending with an amino acid in any one of positions 40 to 104 or a homologous sequence, its use as a carrier for a conjugate, particularly in combination with a polysaccharide, and a process for producing the peptide as well as vaccines comprising said peptide.

## Claims

### Claim at position 1

1-25 (Canceled).

### Claim at position 2

26: A conjugate comprising a peptide and an immunoreactive molecule, wherein the peptide has 40 to 200 residues and comprises an amino acid sequence having 40 or more amino acids that are identical or homologous to an amino acid sequence selected from the group consisting of amino acid sequences:
(a) of SEQ ID NO 1, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104;
(b) of SEQ ID NO 2, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104;
(c) of SEQ ID NO 3, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104;
(d) of SEQ ID NO 4, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104; and
(e) of SEQ ID NO 5, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104.

### Claim at position 3 (depends on 26)

27: The conjugate of claim 26, wherein the peptide comprises at least 40 amino acids of the amino acid sequence shown in SEQ ID NO 1, beginning with the amino acid residue in any one of the positions 1 to 5 and ending with an amino acid residue in any one of positions 40 to 104, or a homologous sequence.

### Claim at position 4 (depends on 26)

28: The conjugate of claim 26, wherein the peptide comprises a sequence of at least 40 amino acids that is at least 85% identical to any one of the amino acid sequences of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4,or SEQ ID NO5.

### Claim at position 5 (depends on 26)

29: The conjugate of claim 26, wherein the peptide comprises a sequence of at least 70 amino acid residues having an amino acid sequence that is identical or homologous to an amino acid sequence of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, or SEQ ID NO 5 beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of the positions 70 to 104.

### Claim at position 6 (depends on 26)

30: The conjugate of claim 26, wherein the peptide comprises a sequence of at least 100 amino acid residues having an amino acid sequence that is identical or homologous to an amino acid sequence of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4, or SEQ ID NO 5 beginning with the amino acid residue in any one of the positions 1 to 5 and ending with the amino acid residue in any one of the positions 100 to 104.

### Claim at position 7 (depends on 26)

31: The conjugate of claim 26, wherein the peptide comprises the amino acid sequence of SEQ ID NO 1.

### Claim at position 8 (depends on 26)

32: The conjugate of claim 26, wherein the peptide comprises an amino acid sequence which is at least 85% identical to the amino acid sequence of SEQ ID NO 1.

### Claim at position 9 (depends on 26)

33: The conjugate of claim 26, wherein the peptide further comprises an additional cysteine residue.

### Claim at position 10 (depends on 33)

34: The conjugate of claim 33, wherein the cysteine residue is located at one terminus of the peptide sequence.

### Claim at position 11 (depends on 26)

35: The conjugate of claim 26, wherein the immunoreactive molecule is a polysaccharide.

### Claim at position 12 (depends on 35)

36: The conjugate of claim 35, wherein the polysaccharide is Polysaccharide C of Neisseria meningitidis, Neisseria gonorrhoeae or Haemophilus influenzae.

### Claim at position 13 (depends on 26)

37: The conjugate of claim 26, further comprising an additional cysteine residue in the peptide, a bifunctional linker and a polysaccharide, wherein the peptide is bonded to the linker via the thiol group of the cysteine and the polysaccharide is bonded to the other functional group of the linker via a hydroxy, carboxy, or amino group.

### Claim at position 14 (depends on 26)

38: The conjugate of claim 26, wherein the conjugate comprises one mole of peptide per 50 to 1 moles of immunoreactive molecule.

### Claim at position 15

39: A method of forming a conjugate, comprising linking a peptide to an immunoreactive molecule, thereby forming a peptide-immunoreactive molecule conjugate, wherein the peptide has 40 to 200 residues and comprises an amino acid sequence having 40 or more amino acids that are identical or homologous to an amino acid sequence selected from the group consisting of amino acid sequences:
(a) of SEQ ID NO 1, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104;
(b) of SEQ ID NO 2, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104;
(c) of SEQ ID NO 3, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104;
(d) of SEQ ID NO 4, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104; and
(e) of SEQ ID NO 5, beginning with the amino acid residue in any one of positions 1 to 5 and ending with the amino acid residue in any one of positions 40 to 104.

### Claim at position 16 (depends on 39)

40: The method of claim 39, wherein the immunoreactive molecule is selected from the group of polysaccharides consisting of lipopolysaccharides, O-antigens, bacterial membrane polysaccharides, capsular membrane polysaccharides and fungal membrane polysaccharides.

### Claim at position 17 (depends on 39)

41: The method of claim 39, wherein the immunoreactive molecule is Polysaccharide C of Neisseria meningitidis, Neisseria gonorrhoeae or Haemophilus influenzae.

### Claim at position 18 (depends on 26)

42: A vaccine comprising the conjugate of claim 26 and a conventional carrier, excipient, or diluent.
